

Lanlan Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2141745/publications.pdf>

Version: 2024-02-01

41
papers

1,554
citations

567247

15
h-index

315719

38
g-index

44
all docs

44
docs citations

44
times ranked

2556
citing authors

#	ARTICLE	IF	CITATIONS
1	Colorectal cancer extracellular acidosis decreases immune cell killing and is partially ameliorated by pH-modulating agents that modify tumor cell cytokine profiles.. American Journal of Cancer Research, 2022, 12, 138-151.	1.4	0
2	Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).. American Journal of Cancer Research, 2022, 12, 729-743.	1.4	0
3	Abstract 3709: Synergistic activity of ABT-263 and ONC201 against solid tumor cell lines is associated with suppression of BAG3, Mcl-1, pAkt, and upregulation of Noxa along with Bax cleavage during apoptosis. Cancer Research, 2022, 82, 3709-3709.	0.9	1
4	STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	44
5	Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. Cancer Biology and Therapy, 2022, 23, 417-423.	3.4	7
6	Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget, 2021, 12, 2131-2146.	1.8	3
7	Synergistic imipridone-based drug combinations for treatment of pediatric H3K27M mutant diffuse intrinsic pontine glioma (DIPG). FASEB Journal, 2021, 35, .	0.5	2
8	ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 1572-1583.	4.1	13
9	Abstract 1060: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell death. , 2021, , .		1
10	A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53. ELife, 2021, 10, .	6.0	11
11	Abstract 635: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG). , 2021, , .		0
12	Abstract 1006: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell lines. Cancer Research, 2021, 81, 1006-1006.	0.9	2
13	Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies. Frontiers in Pharmacology, 2021, 12, 747180.	3.5	8
14	EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia, 2021, 23, 792-810.	5.3	26
15	A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs. Oncotarget, 2021, 12, 1980-1991.	1.8	7
16	Targeting the Integrated Stress Response in Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 747837.	3.5	80
17	Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells. Oncotarget, 2021, 12, 2006-2021.	1.8	8
18	Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1 α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports, 2021, 11, 20871.	3.3	9

#	ARTICLE	IF	CITATIONS
19	Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2021, , 1-10.	3.4	6
20	Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. <i>Frontiers in Pharmacology</i> , 2021, 12, 747194.	3.5	14
21	Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. <i>American Journal of Cancer Research</i> , 2021, 11, 4607-4623.	1.4	2
22	Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 751568.	3.5	10
23	Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. <i>Cancer Biology and Therapy</i> , 2021, 22, 607-618.	3.4	10
24	Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.. <i>American Journal of Cancer Research</i> , 2021, 11, 6086-6106.	1.4	1
25	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. <i>Cell Death Discovery</i> , 2020, 6, 57.	4.7	41
26	ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. <i>Neoplasia</i> , 2020, 22, 725-744.	5.3	90
27	Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3K β isoform. <i>Communications Biology</i> , 2020, 3, 267.	4.4	21
28	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. <i>Oncotarget</i> , 2020, 11, 3753-3769.	1.8	18
29	DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2020, 22, iii299-iii299.	1.2	1
30	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. <i>Cell Cycle</i> , 2018, 17, 468-478.	2.6	34
31	Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 11.	8.6	37
32	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. <i>Cell Cycle</i> , 2017, 16, 1790-1799.	2.6	53
33	Tissue TGF- β 2 expression following conventional radiotherapy and pulsed low-dose-rate radiation. <i>Cell Cycle</i> , 2017, 16, 1171-1174.	2.6	20
34	The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. <i>Cell Cycle</i> , 2017, 16, 1193-1200.	2.6	39
35	A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 3662-3676.	1.8	27
36	Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 151-161.	0.5	55

#	ARTICLE	IF	CITATIONS
37	Discovery and clinical introduction of first-in-class imipridone ONC201. <i>Oncotarget</i> , 2016, 7, 74380-74392.	1.8	111
38	Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1710-1719.	3.4	15
39	Acoustic separation of circulating tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4970-4975.	7.1	632
40	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. <i>Cancer Research</i> , 2015, 75, 3842-3852.	0.9	89
41	Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. <i>Oncology Reports</i> , 2012, 28, 883-888.	2.6	1